DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the DBV second quarter financial results and business update conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press the pound key, then one. Please note this event is being recorded. I would now like to turn the conference over to Katie Matthews, Investor Relations. Please go ahead. Thank you. This afternoon, DBV Technologies issued a press release that outlines our financial results for the three and six months ended June 30th, 2024. This press release is available in the Press Releases section of the DBV Technologies website. Before we begin, Please note that today's call may include a number of forward-looking statements, including but not limited to comments regarding our clinical and regulatory development plans, the design of our anticipated clinical trials, the timing and results of interactions with regulatory agencies, our forecast of our cash runway, and the ability of any of our product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements are based on assumptions that are subject to risks and uncertainties that could cause the company's actual results to differ significantly from those suggested by these statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. These refer to the company's filings with the SEC and the French AMF for information concerning risk factors that could cause the company's actual results to differ...